Zymeworks (NYSE:ZYME) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
This is a summary of recent recommendations for Zymeworks and Bio-Path, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
28.4% of Zymeworks shares are owned by institutional investors. 4.8% of Zymeworks shares are owned by insiders. Comparatively, 8.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Zymeworks has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500.
Valuation & Earnings
This table compares Zymeworks and Bio-Path’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Zymeworks||$53.02 million||11.24||-$36.56 million||($1.26)||-14.75|
Bio-Path has lower revenue, but higher earnings than Zymeworks.
This table compares Zymeworks and Bio-Path’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Zymeworks beats Bio-Path on 6 of the 11 factors compared between the two stocks.
Zymeworks Company Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Bio-Path Company Profile
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.